Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.47 Analyst target: $21.40 Upside: 152.66%
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
See the full interactive analysis & chart →Informational only — not investment advice.